Perioperative cardioprotection as a measure to reduce the risk of posthospital cardiovascular complications (cohort study)
https://doi.org/10.24884/2078-5658-2025-22-1-6-15
Abstract
The objective was to study the incidence of the late cardiovascular complications depending on the use of perioperative cardioprotection in patients with high cardiac risk.
Materials and methods. We analyzed data of medical cards and telephone interviews of 307 patients aged 47 to 85 (67 [63–71]) years who underwent surgical procedures a year before the interview. Perioperative pharmacological cardioprotection (dexmedetmidine or phosphocreatin) was used in 168 (54.7 %) patients. The endpoints of the study were composite outcome (one or more cardiac events), MACCE (cardiac mortality, myocardial infarction, stroke or a combination of these) and 1-year cardiac mortality. To process the data, we used logistic regression with the calculation of the odds ratio (OR) and 95% confidence interval (95% CI) and ROC analysis.
Results. During 12 months after vascular surgery, various cardiac events (composite outcome) developed in 29.3 % of patients, including MACCE in 11.4 % of cases and cardiac mortality in 3.3 %. Patients who received and did not receive cardioprotection had a different risk of composite outcome (OR 0.5392, 95 % CI 0.3287–0.8846, р=0.014) and risk of MACCE (OR 0.4835, 95 % CI 0.2372–0.9852, p = 0.041). Perioperative cardioprotection had no effect on the risk of 1-year cardiac mortality (OR 0.3994, 95 % CI 0.1177–1.3556, р = 0.125).
Conclusion. Within one year after vascular surgery, more than 29 % of patients with high cardiac risk develop one or more cardiac events (composite outcome), including cardiac mortality in 3.3 % of cases. Perioperative cardioprotection with dexmedetomidine or phosphocreatine reduces the risk of composite outcome and the risk of MACCE, without reducing one year cardiac mortality.
About the Authors
D. A. Sokolov
Yaroslavl State Medical University ; Yaroslavl Regional Clinical Hospital
Russian Federation
Russian Federation
Sokolov Dmitrii A., Cand. of Sci. (Med.), Associate Professor, Associate Professor of Anesthesiology and Intensive Care Department; Intensivist
Author ID: 969854
5, Revolutsionnaya str., Yaroslavl, 150000
7, Yakovlevskaya str., Yaroslavl, 150062
I. A. Kozlov
Moscow Regional Research Clinical Institute named after M. F. Vladimirsky
Russian Federation
Russian Federation
Kozlov Igor A., Dr. of Sci. (Med.), Professor, Moscow Regional Research Clinical Institute
AuthorID: 646202
7, Yakovlevskaya str., Yaroslavl, 150062
References
1. Zabolotskikh I. B., Potievskaya V. I., Bautin A. E. et al. Perioperative management of patients with coronary artery disease. Russian Journal of Anesthesiology and Reanimatology, 2020, no. 3, pp. 5–16. (In Russ.). https://doi.org/10.17116/anaesthesiology20200315.
2. Kozlov I. A., Sokolov D. A., Lyuboshevsky P. A. The effectiveness of dexmedetomidine cardioprotection during vascular surgery in high cardiac risk patients. Messenger of Anesthesiology and Resuscitation, 2024, vol. 21, no. 2, pp. 6–17. (In Russ.). https://doi.org/10.24884/2078-5658-2024-21-2-6-17.
3. Kozlov I. A., Sokolov D. A., Lyuboshevsky P. A. The effectiveness of phosphocreatine cardioprotection during vascular surgery in high cardiac risk patients. Messenger of Anesthesiology and Resuscitation, 2024, vol. 21, no. 3, pp. 6–16. (In Russ.). https://doi.org/10.24884/2078-5658-2024-21-3-6-16.
4. Murashko S. S., Berns S. A., Pasechnik I. N. Cardiovascular complications in non-cardiac surgery: what remains out of sight? Cardiovascular Therapy and Prevention, 2024, vol. 23, no. 1, pp. 3748. (In Russ.). https://doi.org/10.15829/1728-8800-2024-3748.
5. Sokolov D. A., Kagramanyan M. A., Kozlov I. A. Calculated hematological indices as predictors of cardiovascular complications in noncardiac surgery (Pilot Study). Messenger of Anesthesiology and Resuscitation, 2022, vol. 19, no. 2, pp. 14–22. (In Russ.). https://doi.org/10.21292/2078-5658-2022-19-2-14-22.
6. Sokolov D. A., Lyuboshevsky P. A., Staroverov I. N., Kozlov I. A. Posthospital Cardiovascular Complications in Patients after Non-Cardiac Surgery. Messenger of Anesthesiology and Resuscitation, 2021, vol. 18, no. 4, pp. 62–72. (In Russ.). https://doi.org/10.21292/2078-5658-2021-18-4- 62-72.
7. Sumin A. N., Duplyakov D. V., Belyalov F. I. et al. Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023. Russian Journal of Cardiology, 2023, vol. 28, no. 8, pp. 5555. (In Russ.). https://doi.org/10.15829/1560-4071-20235555.
8. Chaulin А. M., Grigorieva Yu. V., Pavlova T. V. et al. Diagnostic significance of complete blood count in cardiovascular patients. Rossiysky Kardiologicheskiy Journal. 2020, vol. 25, no. 12, pp. 172–177. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3923.
9. Ackland G. L., Abbott T. E. F., Cain D. et al. Preoperative systemic inflammationand perioperative myocardial injury: prospective observational multicentre cohort study of patients undergoing non-cardiac surgery. British J. Anaesth, 2019, vol. 122, no. 2, pp. 180–187. https://doi.org/10.1016/j.bja.2018.09.002.
10. Álvarez-Garcia J., Popova E., Vives-Borrás M. et al. Myocardial injury after major non-cardiac surgery evaluated with advanced cardiac imaging: a pilot study. BMC Cardiovasc Disord, 2023, vol. 23, no. 1, pp. 78. https://doi.org/10.1186/s12872-023-03065-6.
11. Beaulieu R. J., Sutzko D. C., Albright J. et al. Association of High mortality with postoperative myocardial infarction after major vascular surgery despite use of evidence-based therapies. JAMA Surg, 2020, vol. 155, no. 2, pp. 131–137. https://doi.org/10.1001/jamasurg.2019.4908.
12. Bhutta H., Agha R., Wong J. et al. Neutrophil-lymphocyte ratio predicts medium-term survival following elective major vascular surgery: a cross-sectional study. Vasc. Endovasc. Surg, 2011, vol. 45, no. 3, pp. 227–231. https://doi.org/10.1177/1538574410396590.
13. Bignami E., Greco T., Barile L. et al. The effect of isoflurane on survival and myocardial infarction: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth, 2013, vol. 27, no. 1, pp. 50–58. https://doi.org/10.1053/j.jvca.2012.06.007.
14. Blessberger H., Lewis S. R., Pritchard M. W. et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev, 2019, vol. 9, no. 9, pp. CD013438. https://doi.org/10.1002/14651858.CD013438.
15. Borger M., von Haefen C., Bührer C. et al. Cardioprotective effects of dexmedetomidine in an oxidative-stress in vitro model of neonatal rat cardiomyocytes. Antioxidants (Basel), 2023, vol. 12, no. 6, pp. 1206. https://doi.org/10.3390/antiox12061206.
16. Choi B., Oh A. R., Park J. et al. Perioperative adverse cardiac events and mortality after non-cardiac surgery: a multicenter study. Korean J Anesthesiol, 2024, vol. 77, no. 1, pp. 66–76. https://doi.org/10.4097/kja.23043.
17. Devereaux P. J., Duceppe E., Guyatt G. et al. MANAGE Investigators. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet, 2018, vol. 391, no. 10137, pp. 2325–2334. https://doi.org/10.1016/S0140-6736(18)30832-8.
18. Devereaux P. J., Goldman L., Cook D. J. et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ, 2005, vol. 173, no. 6, pp. 627–634. https://doi.org/10.1503/cmaj.050011.
19. Durmus G., Belen E., Can M. M. Increased neutrophil to lymphocyte ratio predicts myocardial injury in patients undergoing non-cardiac surgery. Heart Lung, 2018, vol. 47, no. 3, pp. 243–247. https://doi.org/10.1016/j.hrtlng.2018.01.005.
20. Gillis C., Ljungqvist O., Carli F. Prehabilitation, enhanced recovery after surgery, or both? A narrative review. Br J Anaesth, 2022, vol. 128, no. 3, pp. 434–448. https://doi.org/10.1016/j.bja.2021.12.007.
21. Green S. B. How many subjects does it take to do a regression analysis. Multivariate Behav Res, 1991, vol. 26, no. 3, pp. 499–510. https://doi.org/10.1207/s15327906mbr2603_7.
22. Halvorsen S., Mehilli J., Cassese S. et al. ESC Scientific Document GrouP. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J, 2022, vol. 43, no. 39, pp. 3826–3924. https://doi.org/10.1093/eurheartj/ehac270.
23. Handke J., Scholz A. S., Gillmann H. J. et al. elevated presepsin is associated with perioperative major adverse cardiovascular and cerebrovascular complications in elevated-risk patients undergoing noncardiac surgery: the leukocytes and cardiovascular perioperative events study. Anesth Analg, 2019, vol. 128, no. 6, pp. 1344–1353. https://doi.org/10.1213/ANE.0000000000003738.
24. Imtiaz F., Shafique K., Mirza S. S. et al. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int. Arch. Med, 2012, vol. 5, no. 1, pp. 2. https://doi.org/10.1186/1755-7682-5-2.
25. Kampman J. M., Hermanides J., Hollmann M. W. et al. Mortality and morbidity after total intravenous anaesthesia versus inhalational anaesthesia: a systematic review and meta-analysis. EClinicalMedicine, 2024, vol. 72, pp. 102636. https://doi.org/10.1016/j.eclinm.2024.102636.
26. Khan A., Johnson D. K., Carlson S. et al. NT-Pro BNP predicts myocardial injury post-vascular surgery and is reduced with CoQ10: a randomized double-blind trial. Ann Vasc Surg, 2020, vol. 64, pp. 292–302. https://doi.org/10.1016/j.avsg.2019.09.017.
27. Larmann J., Handke J., Scholz A. S. et al. Preoperative neutrophil to lymphocyte ratio and latelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery. BMC Cardiovascular Disorders, 2020, vol. 20, pp. 230–239. https://doi.org/10.1186/s12872-020-01500-6.
28. Lawrence C. J., Prinzen F. W., de Lange S. The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. Anesth Analg, 1996, vol. 82, no. 3, pp. 544–550. https://doi.org/10.1097/00000539-199603000-00021.
29. Ling M. Y., Song Y. P., Liu C. et al. Protection of exogenous phosphocreatine for myocardium in percutaneous coronary intervention related to inflammation. Rev Cardiovasc Med, 2022, vol. 23, no. 3, pp. 89. https://doi.org/10.31083/j.rcm2303089.
30. Lionetti V., Barile L. Perioperative cardioprotection: back to bedside. Minerva Anestesiol, 2020, vol. 86, no. 4, pp. 445–454. https://doi.org/10.23736/S0375-9393.19.13848-5.
31. Mangano D. T., Browner W. S., Hollenberg M. et al. Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research GrouP. JAMA, 1992, vol. 268, no. 2, pp. 233–239. https://doi.org/10.1001/jama.268.2.233.
32. Mastroroberto P., Chello M., Zofrea S. et al. Cardioprotective Effects of Phosphocreatine in Vascular Surgery. Vasc Endovasc Surgery, 1995, vol. 29, no. 4, pp. 255–260. https://doi.org/10.1177/153857449502900401.
33. Oh A. R., Park J., Lee J. H. et al. Association between perioperative adverse cardiac events and mortality during one-year follow-up after noncardiac surgery. J Am Heart Assoc, 2022, vol. 11, no. 8, pp. e024325. https://doi.org/10.1161/JAHA.121.024325.
34. Paulus W. J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol, 2013, vol. 62, no. 4, pp. 263–71. https://doi.org/10.1016/j.jacc.2013.02.092.
35. Puelacher C., Gualandro D. M., Glarner N. et al. BASEL-PMI Investigators. Long-term outcomes of perioperative myocardial infarction/injury after non-cardiac surgery. Eur Heart J., 2023, vol. 44, no. 19, pp. 1690–1701. https://doi.org/10.1093/eurheartj/ehac798.
36. Sazgary L., Puelacher C., Lurati Buse G. et al. BASEL-PMI Investigators. Incidence of major adverse cardiac events following non-cardiac surgery. Eur Heart J Acute Cardiovasc Care, 2021, vol. 10, no. 5, pp. 550–558. https://doi.org/10.1093/ehjacc/zuaa008.
37. Shannon A. H., Mehaffey J. H., Cullen J. M. et al. Preoperative beta blockade is associated with increased rates of 30-day major adverse cardiac events in critical limb ischemia patients undergoing infrainguinal revascularization. J Vasc Surg, 2019, vol. 69, no. 4, pp. 1167–1172.e1. https://doi.org/10.1016/j.jvs.2018.07.077.
38. Smilowitz N. R., Redel-Traub G., Hausvater A. et al. Myocardial injury after noncardiac surgery: A systematic review and meta-analysis. Cardiol Rev, 2019, vol. 27, no. 6, pp. 267–273. https://doi.org/10.1097/CRD.0000000000000254.
39. Soliman R., Zohry G. The myocardial protective effect of dexmedetomidine in high-risk patients undergoing aortic vascular surgery. Ann Card Anaesth, 2016, vol. 19, no. 4, pp. 606–613. https://doi.org/10.4103/0971-9784.191570.
40. Strickland S. S., Quintela E. M., Wilson M. J., Lee M. J. Long-term major adverse cardiovascular events following myocardial injury after non-cardiac surgery: meta-analysis. BJS Open, 2023, vol. 7, no. 2, pp. zrad021. https://doi.org/10.1093/bjsopen/zrad021.
41. Strumia E., Pelliccia F., D’Ambrosio G. Creatine phosphate: pharmacological and clinical perspectives. Adv Ther, 2012, vol. 29, no. 2, pp. 99–123. https://doi.org/10.1007/s12325-011-0091-4.
42. Sultan P., Edwards M. R., Gutierrez del Arroyo A. et al. Cardiopulmonary exercise capacity and preoperative markers of inflammation. Mediators Inflamm, 2014, vol. 2014, pp. 727451. https://doi.org/10.1155/2014/727451.
43. Torregroza C., Raupach A., Feige K. et al. Perioperative cardioprotection: general mechanisms and pharmacological approaches. Anesth Analg, 2020, vol. 131, no. 6, pp. 1765–1780. https://doi.org/10.1213/ANE.0000000000005243.
44. Wang K., Wu M., Xu J. et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis. Br J Anaesth, 2019, vol. 123, no. 6, pp. 777–794. https://doi.org/10.1016/j.bja.2019.07.027.
45. Yan P., Chen S. Q., Li Z. P. et al. Effect of exogenous phosphocreatine on cardiomycytic apoptosisand expression of Bcl-2 and Bax after cardiopulmonary resuscitation in rats. World J. Emerg. Med, 2011, vol. 2, no. 4, pp. 291–295. https://doi.org/10.5847/wjem.j.1920-8642.2011.04.009.
46. Yang Y. F., Wang H., Song N. et al. Dexmedetomidine attenuates ischemia/reperfusion-induced myocardial inflammation and apoptosis through inhibiting endoplasmic reticulum stress signaling. J Inflamm Res, 2021, vol. 14, 1217–1233. https://doi.org/10.2147/jir.S292263.
47. Zhang W., Zhang H., Xing Y. Protective effects of phosphocreatine administered post-treatment combined with ischemic post-conditioning on rat hearts with myocardial ischemia/reperfusion injury. J. Clin. Med. Res, 2015, vol. 7, no. 4, pp. 242–247. https://doi.org/10.14740/jocmr2087w.
Review
For citations:
Sokolov D.A., Kozlov I.A. Perioperative cardioprotection as a measure to reduce the risk of posthospital cardiovascular complications (cohort study). Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2025;22(1):6-15. (In Russ.) https://doi.org/10.24884/2078-5658-2025-22-1-6-15
Email this article 